^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

EGFR negative

i
Entrez ID:
30d
Polygenic risk score and lung adenocarcinoma risk among never-smokers by EGFR mutation status-a brief report. (PubMed, J Thorac Oncol)
We found that the PRS was more strongly associated with EGFR-positive LUAD compared to EGFR-negative LUAD, where the association between the fourth quartile of the PRS and EGFR-positive LUAD (OR=8.63, 95% CI:5.67, 13.14) was significantly higher than the association between the fourth quartile of the PRS with EGFR-negative LUAD (OR=3.50, 95% CI: 2.44, 5.00) (p-heterogeneity=3.66x10-3). Our findings suggest that germline genetic susceptibility may be differentially associated with LUAD in never-smoking female East Asian patients depending on the cancer's mutation status, which may have important public health and clinical implications.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR positive • EGFR negative
2ms
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (clinicaltrials.gov)
P2, N=117, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative
|
Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
2ms
HER2 Assay for the Detection of Low Expressing HER2 (IHC Score 1+/0) in Circulating Tumor Cells Enriched from Peripheral Blood using the CELLSEARCH® System (SABCS 2024)
Linearity testing, where the cell lines were spiked in 7.5mL blood, showed high levels of reproducibility across the clinical range (1000 cells to 0) with an R2 = 0.99. The CELLSEARCH® CTC-HER2 Low test meets a critical clinical need that breast cancer patients, positive or classified as negative from a tissue biopsy, in need of a current evaluation of their metastatic breast cancer HER2 status, through any line of treatment, can do so from one blood draw using a test that can detect HER2 expression to very low levels.
Circulating tumor cells • Tumor cell
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • EPCAM (Epithelial cell adhesion molecule)
|
ER positive • HER-2 negative • HER-2 expression • HER-2 underexpression • EGFR positive • EGFR negative • HER-2 negative + ER positive
|
CELLSEARCH®
2ms
Development & Validation of RSC4All: an Artificial Intelligence-driven Machine Learning Nomogram Enhanced with Synthetic Data to Predict RSClin® Results & Guide Adjuvant Treatment of Node-negative HR-positive/HER2-negative Early Breast Cancer (SABCS 2024)
RSC4All accurately reproduces RSClin™ results to support treatment decisions for patients with N0 HR+/HER2- eBC. The incorporation of SD further enhanced the predictive accuracy of the ML tool, supporting the value of AI-driven data augmentation in oncology.
Clinical • Machine learning
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • EGFR negative • HR positive + HER-2 negative • HER-2 negative + HR negative • HER-2 positive + HR negative
|
Oncotype DX Breast Recurrence Score®Test
2ms
Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trial. (PubMed, ESMO Open)
OAC may be subdivided into three immune-related subgroups which undergo modulation in response to neoadjuvant therapy with marked suppression of the immune microenvironment in HER2-positive/immune-high tumours.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
|
HER-2 positive • HER-2 expression • EGFR positive • EGFR negative
|
capecitabine • oxaliplatin • sapitinib (AZD8931)
3ms
Successful treatment of GEMOX regimen combined with nimotuzumab in the pancreatic cancer with wild KRAS and mutant BRCA: a report of two cases. (PubMed, AME Case Rep)
We used the combined chemotherapy of gemcitabine (1,000 mg/m2) + oxaliplatin (135 mg/m2) + nimotuzumab (400 mg). Then, the patients were treated with oral olaparide (600 mg/day) for one year, and survived without tumor progress for more than 1.5 years. These two cases achieved excellent effects of precise chemotherapy, which provided an important reference for the treatment of pancreatic cancer patients with wild KRAS and mutant BRCA.
Journal • BRCA Biomarker
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRCA (Breast cancer early onset)
|
KRAS mutation • KRAS wild-type • RAS wild-type • EGFR negative • BRCA mutation
|
gemcitabine • oxaliplatin • TheraCIM (nimotuzumab)
3ms
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (clinicaltrials.gov)
P2, N=117, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2024
Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative
|
Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
3ms
New P4 trial • Real-world evidence • Real-world • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
ALK mutation • EGFR negative
|
AiRuiKa (camrelizumab) • thalidomide
8ms
The value of dynamic FDG PET/CT in the differential diagnosis of lung cancer and predicting EGFR mutations. (PubMed, BMC Pulm Med)
Although both techniques were specific, Ki had a greater specificity than SUVmax when the cut-off value was set at 0.0250 ml/g/min for the differential diagnosis of lung cancer. At a cut-off value of 0.0350 ml/g/min, there was a 0.710 sensitivity for EGFR status prediction. If EGFR testing is not available for a patient, dynamic imaging could be a valuable non-invasive screening method.
Retrospective data • Journal • FDG PET
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR positive • EGFR negative
8ms
Bispecific radioimmunoconjugates exploit receptor heterogeneity for positron emission tomography of tumors expressing HER2 and/or EGFR. (PubMed, iScience)
Bispecific radioimmunoconjugates (bsRICs) that bind HER2 and EGFR were constructed by linking trastuzumab Fab through polyethyleneglycol (PEG24) to EGF...Our results indicate that bsRICs labeled with 64Cu are able to exploit receptor heterogeneity for tumor imaging. PET may select patients for radioimmunotherapy with bsRICs complexed to the β-particle emitter, 177Lu or Auger electron-emitter, 111In in a theranostic approach.
Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 negative • HER-2 expression • EGFR expression • EGFR positive • EGFR negative
|
Herceptin (trastuzumab)
8ms
Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=54, Recruiting, Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Enrolling by invitation --> Recruiting | Trial completion date: Mar 2024 --> Dec 2027 | Trial primary completion date: Mar 2023 --> May 2027
Enrollment status • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
ALK translocation • EGFR negative
|
Inlyta (axitinib) • erfonrilimab (KN046)
8ms
The relative risk of immune checkpoint inhibitor pneumonitis in advanced non-small- cell lung cancer: Meta-analyses of controlled clinical trials. (PubMed, PLoS One)
In advanced NSCLC, ICI treatment was linked to an elevated risk of pneumonitis across all grades (1-5) as well as high-grade occurrences (3-5) compared to chemotherapy. Notably, individuals with squamous histology and high PD-L1 expression, along with those lacking a history of prior treatment, demonstrated a heightened susceptibility to developing immune-related pneumonitis of all grades (1-5) and high grades (3-5). These observations provide valuable insights for clinicians seeking to enhance the management of pulmonary toxicity associated with immunotherapy.
Clinical • Journal • Checkpoint inhibition • Relative risk • PD(L)-1 Biomarker • IO biomarker • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression • PD-L1 overexpression • EGFR expression • EGFR negative • ALK negative • EGFR negative + ALK negative + PD-L1 expression
9ms
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (clinicaltrials.gov)
P2, N=117, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2024 --> Sep 2024 | Trial primary completion date: Jun 2024 --> Sep 2024
Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative
|
Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
9ms
Prognostic Values of CD8+, PARP, and EGFR on Overall Survival in Patients with Triple-Negative Breast Cancer. (PubMed, Asian Pac J Cancer Prev)
Patients with low CD8+, positive PARP, and positive EGFR expressions seem to be associated with poorer overall survival in TNBC. After approximately one year of follow-up, higher survival was observed in patients with high CD8+, negative PARP, and negative EGFR. Staging remains the main predictor of TNBC survival. Therefore, early detection and treatment of TNBC are essential to improve survival.
Journal • PARP Biomarker
|
EGFR (Epidermal growth factor receptor) • CD8 (cluster of differentiation 8) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
|
EGFR expression • CD8 expression • EGFR positive • EGFR negative • CD8-H • CD8 negative
9ms
Patient Age and EGFR-positive Non-small Cell Lung Cancer: A Multicenter Retrospective Study. (PubMed, Anticancer Res)
Patients in their 70s and 80s with non-small cell lung cancer were relatively frequently EGFR gene-positive. To avoid missing out on treatment opportunities, EGFR gene testing should also be performed on patients in this age group.
Retrospective data • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR L858R • EGFR exon 19 deletion • EGFR positive • EGFR negative
9ms
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer. (PubMed, J Clin Oncol)
The addition of palbociclib to fulvestrant did not improve PFS versus fulvestrant alone among patients with hormone receptor-positive/HER2- MBC whose disease had progressed on a previous CDK4/6i plus AI. The increased PFS seen with the addition of avelumab warrants further investigation in this patient population.
P2 data • Journal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
|
HER-2 positive • HR positive • HER-2 negative • EGFR positive • EGFR negative
|
Ibrance (palbociclib) • Bavencio (avelumab) • fulvestrant
10ms
Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial (clinicaltrials.gov)
P3, N=304, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Initiation date: Feb 2024 --> Nov 2024
Enrollment open • Trial initiation date • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
ALK translocation • EGFR negative
|
Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
10ms
Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=37, Recruiting, Chinese University of Hong Kong | Not yet recruiting --> Recruiting | Initiation date: Nov 2024 --> Feb 2024
Enrollment open • Trial initiation date
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR negative
|
Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)
10ms
EGFR and HER2 expression in cervical cancer patients in Ibadan, Nigeria. (PubMed, Ecancermedicalscience)
HER2 was overexpressed in two cervical tissue samples in this study and may be of poor interest as a potential target in the management of cervical cancer patients. Large prospective multi-institutional studies should be considered to further explore the relationship between EGFR and survival in cervical cancer patients.
Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 expression • EGFR expression • EGFR positive • EGFR negative
10ms
Expression of EGFR and p16 in Squamous Cell Carcinoma of External Auditory Canal. (PubMed, Kobe J Med Sci)
In the patients with T3 & T4a EACSCC, prognosis of the patients with positive p16 expression EACSCC tended to be better than those with negative p16 expression. These results suggest the clinical significance of EGFR and p16 expressions in the patients with advanced EACSCC to predict oncological outcomes.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR expression • EGFR negative • CDKN2A negative
10ms
Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=37, Not yet recruiting, Chinese University of Hong Kong | Initiation date: Nov 2023 --> Nov 2024
Trial initiation date
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR negative
|
Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)
11ms
Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101). (PubMed, Cancer Sci)
In patients with unresectable stage III NSCLC with EGFR mutation, durvalumab after CRT is potentially safe and effective. This may be a suitable treatment sequence for these patients.
Clinical • Journal • Real-world evidence • PD(L)-1 Biomarker • Real-world
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR positive • EGFR negative
|
Imfinzi (durvalumab)
12ms
Lower Plasma Amyloid Beta - 42 Levels Associated With Worse Survival in Patients With Glioma. (PubMed, In Vivo)
This study investigated serum Aβ42 levels as a potential biomarker for glioma. The results showed that low serum Aβ42 levels were associated with EGFR expression and poor PFS and OS. Overall, these findings suggest a potential role of Aβ42 as a prognostic marker in astrocytomas.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR expression • EGFR negative
1year
Osimertinib covalently binds to CD34 and eliminates myeloid leukemia stem/progenitor cells. (PubMed, Cancer Res)
Clinical responses were observed in two CD34high AML patients who were treated with osimertinib on a compassionate-use basis. These findings reveal the therapeutic potential of osimertinib for treating CD34high AML and CML and describe an EGFR-independent mechanism of osimertinib-induced cell death in myeloid leukemia.
Journal
|
CD34 (CD34 molecule)
|
EGFR negative
|
Tagrisso (osimertinib)
1year
Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR) (clinicaltrials.gov)
P1/2, N=34, Active, not recruiting, Sangamo Therapeutics | Recruiting --> Active, not recruiting | Trial completion date: Feb 2024 --> Sep 2025 | Trial primary completion date: Dec 2023 --> Apr 2025
Enrollment closed • Trial completion date • Trial primary completion date • Gene therapy
|
EGFR negative
1year
Consolidation therapy of Adebrelimab for stage III unresectable NSCLC after concurrent radiotherapy and chemotherapy (cCRT combined with or without Adebrelimab) (ChiCTR2300075011)
P4, N=120, Recruiting, Shandong First Medical University Affiliated Cancer Hospital; Shandong First Medical University Affiliated Cancer Hospital
New P4 trial
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
MET amplification • ALK fusion • ALK mutation • MET mutation • ROS1 mutation • EGFR negative
|
cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Ariely (adebrelimab)
1year
New P2 trial
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR negative
|
Ariely (adebrelimab)
1year
Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation. (PubMed, Exp Hematol Oncol)
These findings indicated that a ''YB-1/PARP1'' loop conferred resistance to CDK4/6 inhibitors. Furthermore, interrupting the loop can enhance tumor killing in the xenograft tumor model, which provides a promising strategy against drug resistance in breast cancer.
Journal • PARP Biomarker
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HER-2 expression • EGFR negative • PARP1 elevation
1year
Intratumoral thrombosis as a histological biomarker for predicting epidermal growth factor receptor alteration and poor prognosis in patients with glioblastomas. (PubMed, J Neurooncol)
Aberrant but exquisitely regulated EGFR can induce thrombosis in non-MVP vessels in the tumor invasion area and then promote palisading necrosis, followed by hypoxia, abnormal angiogenesis, and further tumor cell invasion.
Journal
|
EGFR (Epidermal growth factor receptor) • CD34 (CD34 molecule) • MVP (Major Vault Protein)
|
EGFR amplification • EGFR expression • EGFR wild-type • EGFR negative • CD34 positive
1year
Clinicopathologic Factors affecting response in patients with Estrogen receptor-positive and Human Epidermal Growth Factor Receptor-negative breast cancer receiving neoadjuvant chemotherapy (SABCS 2023)
Our analysis revealed that patients with higher levels of Ki-67 and lower level of PR expression were more likely to achieve pCR or PR. Also, decrease in Ki-67 index was confirmed to be an important prognostic factor of ER+ HER2- breast cancer. A combination of clinical and molecular factors, such as tumor size, progesterone receptor expression, and Ki-67 expression, can be used to optimize treatment plans and improve outcomes for the patient population.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • AR (Androgen receptor)
|
HER-2 positive • ER positive • HR positive • HER-2 negative • HER-2 expression • EGFR negative • AR expression • HR positive + HER-2 negative • PGR expression • PTEN mutation + HR positive
1year
Exploring the correlation between HER2 alterations and F-FDG PET/CT metabolic parameters and their prognostic value in EGFR-negative non-small-cell lung cancer patients. (PubMed, J Cancer Res Clin Oncol)
The study revealed that low pSUVmax was associated with HER2 alterations in EGFR-negative NSCLC patients, moreover HER2 mutation and HER2 amplification exhibited distinct F-FDG metabolic and clinical characteristics. Furthermore, it explored the prognostic value of HER2 alterations and F-FDG PET/CT metabolic parameters of pSUVmax in EGFR-negative NSCLC patients.
Journal • FDG PET
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative • EGFR negative
1year
AI-based intra-tumor heterogeneity score of Ki67 expression as a prognostic marker for early-stage ER+/HER2- breast cancer. (PubMed, J Pathol Clin Res)
Ki67CL score is shown to be highly significant compared with the standard Ki67 index. In addition, we show that the proposed Ki67CL score can help identify luminal BC patients who can potentially benefit from adjuvant chemotherapy.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative • EGFR negative
1year
New P3 trial • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
ALK translocation • EGFR negative
|
Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
1year
Clinical role of CYP1B1 gene polymorphism in prediction of postoperative chemotherapy efficacy in NSCLC based on individualized health model. (PubMed, Open Life Sci)
In the EGFR-negative group, 13 of the 36 patients relapsed. It can be considered that CYP1B1 gene polymorphism has a good curative effect in postoperative chemotherapy of NSCLC, and it can effectively control the recurrence rate of cancer.
Journal
|
EGFR (Epidermal growth factor receptor) • CYP1B1 (Cytochrome P450 Family 1 Subfamily B Member 1)
|
EGFR negative
1year
Enrollment closed
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative
|
Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
1year
Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong (ESMO Asia 2023)
The liquid-first approach enhances the yield of rare mutations by tissue NGS which is resource-dependent. It benefits regions where tissue biopsy is a rate limiting factor and EGFR mutations are prevalent.
Clinical • Next-generation sequencing • Metastases
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
TP53 mutation • BRAF mutation • PIK3CA mutation • EGFR T790M • EGFR exon 20 insertion • MET exon 14 mutation • MET mutation • EGFR exon 20 mutation • EGFR negative • EGFR mutation + PIK3CA mutation • EGFR exon 20 insertion + EGFR T790M • HER-2 exon 23 mutation
|
cobas® EGFR Mutation Test v2 • Oncomine Precision Assay
1year
Difference in Radiosensitivity Depending on the Presence and Absence of EGFR Mutations: Clinical and In Vitro Analyses. (PubMed, Int J Radiat Oncol Biol Phys)
Our data suggest that patients with EGFR mutation-positive NSCLC are more radiosensitive than those with negative EGFR mutations.
Preclinical • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR negative • EGFR H1975
1year
Atezolizumab for EGFR-mutated Non-small Cell Lung Cancer Patients: An Observation Study in Ibaraki Group (ATTENTION-IBARAKI). (PubMed, Anticancer Res)
Efficacy of atezolizumab in EGFR-mutated NSCLC patients could be comparable to that for EGFR-negative patients. To prolong the survival of EGFR-mutated NSCLC patients, appropriate selection and sequencing of EGFR for tyrosine kinase inhibitors, as well as immune checkpoint inhibitors, anti-tumor agents, and anti-angiogenic agents are important.
Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR negative
|
Tecentriq (atezolizumab)
1year
Trial suspension
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative
|
Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
1year
New P2 trial
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR negative
|
Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)
over1year
A study of clinical and molecular characteristics in bilateral primary breast cancer. (PubMed, Cancer Med)
Our study suggested that BPBC may tend to be lobular carcinoma and have the HR+/HER2- subtype. Although our study did not find specific germline and somatic mutations in BPBC, more research is needed for verification.
Journal • BRCA Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • BRCA2 (Breast cancer 2, early onset)
|
TP53 mutation • HR positive • HER-2 negative • EGFR negative